Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2003
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company operates through two segments: Alcon United States and Alcon International. As of December 31, 2003, Nestlé S.A. owned approximately 75% of the outstanding common shares.
Key Financial Metrics (Year Ended Dec 31, 2003)
| Metric | 2003 (in millions) | 2002 (in millions) | Change |
|---|---|---|---|
| Sales | $3,406.9 | $3,009.1 | +13.2% |
| Gross Profit | $2,401.0 | $2,116.4 | +13.4% |
| Gross Margin | 70.5% | 70.3% | +0.2 pts |
| Operating Income | $879.4 | $703.7 | +25.0% |
| Net Earnings | $595.4 | $466.9 | +27.5% |
| Diluted EPS | $1.92 | $1.53 | +25.5% |
| Operating Cash Flow | $915.4 | $701.4 | +30.5% |
| Total Debt | $1,410.3 | $1,876.7 | -24.9% |
| Cash & Equivalents | $1,086.0 | $967.9 | +12.2% |
| Net Debt | $324.3 | $908.8 | -64.3% |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 13.2% (9.0% in constant currency). Growth was driven by pharmaceuticals (+20.1%), surgical products (+10.2%), and consumer eye care (+6.4%). Currency fluctuations had a favorable impact of 4.2% on reported sales.
- Profitability: Operating income margin improved to 25.8% from 23.4%. This was aided by a one-time $8.2 million pre-tax gain from the sale of a manufacturing plant in Madrid, Spain, and the absence of significant one-time charges that impacted 2002 (such as the SKBM microkeratome recall costs and deferred compensation plan changes).
- Debt Reduction: Net debt decreased significantly by $584.5 million to $324.3 million, driven by strong operating cash flows and the reduction of short-term borrowings.
- Segment Performance:
- Alcon United States: Sales grew 9.4% to $1,785.9 million; operating income grew 17.6% to $794.3 million.
- Alcon International: Sales grew 17.8% (8.5% constant currency) to $1,621.0 million; operating income grew 20.3% to $514.9 million.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Dividends: The Board expects to declare a dividend of CHF 0.72 per share (approx. $0.57) for 2003 operations, payable in May 2004, subject to shareholder approval.
- Capital Expenditures: Capital expenditures were $157.9 million in 2003. Commitments of $38.6 million remain for facility upgrades and a new administrative/training center in Fort Worth, Texas.
- R&D Pipeline: Significant investments continue in glaucoma, age-related macular degeneration (AMD), and refractive surgery. Key upcoming approvals include AcrySof ReSTOR (2005) and Patanol once-a-day (2004).
Key Risks & Contingencies:
- Patent Expirations: The U.S. patent for Ciloxan expires in June 2004. Alcon is transitioning sales to Vigamox to mitigate this impact.
- Regulatory & Pricing Pressure: Ongoing pressure from third-party payors, government reimbursement cuts (notably in Japan), and potential importation of lower-priced drugs from Canada.
- Currency Risk: Significant exposure to the Euro and Japanese Yen; a strengthening U.S. dollar could negatively impact reported sales and profits.
- Supply Chain: Reliance on single-source suppliers for active ingredients in key products (e.g., Travatan, Patanol, Vigamox).
Investor Verification Checklist
- Patent Cliff Mitigation: Verify the market share transition from Ciloxan to Vigamox as the June 2004 patent expiration approaches.
- Japan Market Performance: Monitor sales trends in Japan, the company's second-largest market, given historical government reimbursement cuts and pricing pressures.
- Constant Currency Growth: Distinguish between reported growth and constant currency growth (9.0% vs 13.2%) to assess organic operational performance independent of the strong Euro.
- Dividend Approval: Confirm shareholder approval of the proposed CHF 0.72 dividend at the April 2004 Annual General Meeting.
- Net Debt Trajectory: Track the continued reduction of net debt and the utilization of the $2.0 billion commercial paper facility.